Indeed, by using the ELISA test, we demonstrated an interesting association between sPD-L1 levels and elevated metabolic tumor burden, suggesting a larger release of malignant particles into the bloodstream from extended tumors. This evidence concerns the gene SPDL1 and neoplasm.